Please login to the form below

Not currently logged in
Email:
Password:

MorphoSys and Novartis extend biopharmaceuticals tie-up

MorphoSys and Novartis extend their existing 2004 tie-up to discover and develop biopharmaceuticals

German biotech MorphoSys and Swiss-based Novartis have extended their existing 2004 tie-up to discover and develop biopharmaceuticals.

Per the agreement, Novartis will make a 10-year commitment to MorphoSys' HuCAL technology (Human Combinatorial Antibody Library), which involves in-vitro generation of highly specific and fully human antibodies.

Novartis has the option to prolong the collaboration for a further two years or to conclude the alliance after seven years in certain limited circumstances.

Both parties will engage in around double the annual number of therapeutic antibody discovery programmes, compared with the previous 2004 alliance, which encompasses a wide range of diseases.

MorphoSys also has options to participate in certain development activities in various programmes, with part of the early stage costs funded by Novartis. Under the co-development options, MorphoSys may elect to participate in these projects through cost and profit sharing.

Potentially big gains for MorphoSys
Based on a 10-year term, total annual payments could add up to over USD 600m in technology access, fees and R&D funding, excluding reimbursement of R&D costs related to early stage development activities. The expanded alliance also includes rights to co-detail co-developed products in specific territories through creation of MorphoSys' own sales force.

Total payments under the agreement, including committed payments and probability-weighted success-based milestones, contingent upon successful clinical development and market approval of multiple products, could exceed USD 1bn, if the collaboration runs to term. MorphoSys would also be entitled to royalty payments and/or profit sharing on any future product sales.

3rd December 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

The ALS patient journey
Nick Goldup is the Director of Care Improvement at the Motor Neuron Disease Association (MNDA). Here, he offers his insights into the journey for patients with ALS and explores the...
Equipping your medical affairs teams with solutions to navigate the healthcare landscape
Dr Tyler Ray, OPEN Health Medical Communications...
Protein degraders
Can protein degraders unlock ‘undruggable’ drug targets?
Exploring a new and exciting area of small-molecule drug discovery...

Infographics